Shares of Proteon Therapeutics (NASDAQ:PRTO) have been assigned a consensus recommendation of “Hold” from the six research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $3.00.
PRTO has been the subject of several research reports. Robert W. Baird set a $3.00 target price on Proteon Therapeutics and gave the company a “hold” rating in a research note on Wednesday, March 14th. Zacks Investment Research upgraded Proteon Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. ValuEngine upgraded Proteon Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Cowen restated a “hold” rating on shares of Proteon Therapeutics in a research note on Thursday, May 10th. Finally, HC Wainwright upgraded Proteon Therapeutics from a “neutral” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Thursday, May 10th.
An institutional investor recently raised its position in Proteon Therapeutics stock. Renaissance Technologies LLC boosted its holdings in Proteon Therapeutics (NASDAQ:PRTO) by 17.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 201,500 shares of the biopharmaceutical company’s stock after acquiring an additional 29,600 shares during the quarter. Renaissance Technologies LLC owned 1.14% of Proteon Therapeutics worth $383,000 at the end of the most recent quarter. 50.18% of the stock is currently owned by hedge funds and other institutional investors.
Proteon Therapeutics traded up $0.10, reaching $2.10, during trading hours on Friday, Marketbeat reports. 16,662 shares of the company’s stock were exchanged, compared to its average volume of 31,251. Proteon Therapeutics has a twelve month low of $1.10 and a twelve month high of $2.85. The company has a market cap of $37.12 million, a P/E ratio of -0.99 and a beta of 1.53.
Proteon Therapeutics (NASDAQ:PRTO) last issued its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. analysts forecast that Proteon Therapeutics will post -1.48 earnings per share for the current fiscal year.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.